Biosimilars and GLP-1 medications are reshaping the pharmaceutical landscape, presenting both opportunities and challenges for IDN pharmacy operations. As adoption accelerates and demand surges, understanding the clinical, financial, and operational implications of these drug categories has become essential for effective pharmacy management. In this session, explore how these medications are impacting formulary decisions, cost structures, patient access, and overall supply chain strategy.

Join pharmacy leaders as they share real-world experiences managing biosimilar integration and GLP-1 demand, offering practical insights into optimizing utilization while controlling costs and maintaining quality outcomes.

Learning Objectives:
1. Analyze the financial and clinical impact of biosimilar adoption on formulary management and total cost of care within your organization.
2. Evaluate strategies for managing GLP-1 drug demand, access, and utilization amid supply constraints and reimbursement challenges.
3. Identify operational considerations for integrating biosimilars into existing workflows, including clinician education and patient transition protocols.
4. Develop approaches to balance cost savings opportunities with quality, safety, and patient access priorities across both drug categories.